Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Bronchiolitis Obliterans Syndrome × abexinostat × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Other hematologic neoplasm 1 Lymphoid 1

Conditions

Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Hodgkin Disease 2 Neoplasms by Site 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Bronchiolitis Obliterans Syndrome 1

Interventions

KW-2478 2 milatuzumab 1 abexinostat 1 Hsp90 inhibitor KU757 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01149668 2013-06-19

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Pharmacyclics LLC.

Phase 1 Completed

LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡